Sakellariou G, Markianos M, Tsichlakis N, Kartakis D
Psychiatry Res. 1987 Mar;20(3):221-7. doi: 10.1016/0165-1781(87)90082-5.
The genetic influence on plasma dopamine-beta-hydroxylase and the possible differences in the activities of this enzyme between schizophrenic patients and their healthy first degree relatives were studied in 103 members of 21 families. The activities of the 24 patients did not differ from those of their 37 healthy siblings or their 42 parents. A control group of 52 subjects without family history of the illness had similar enzyme activities. The correlation coefficients between patients and healthy siblings, between patients and parents, and between healthy siblings and parents were all around 0.50, as is expected for subjects who share half of their genes. Thus, although plasma dopamine-beta-hydroxylase activity is genetically determined, it neither differentiates schizophrenic from healthy family members nor differentiates subjects with a family history of the illness from those without such a history.
对21个家庭的103名成员进行研究,以探讨基因对血浆多巴胺-β-羟化酶的影响,以及精神分裂症患者与其健康的一级亲属之间该酶活性可能存在的差异。24名患者的酶活性与其37名健康兄弟姐妹或42名父母的酶活性并无差异。52名无该疾病家族史的对照组受试者具有相似的酶活性。患者与健康兄弟姐妹之间、患者与父母之间以及健康兄弟姐妹与父母之间的相关系数均约为0.50,这与共享一半基因的受试者预期情况相符。因此,尽管血浆多巴胺-β-羟化酶活性由基因决定,但它既不能区分精神分裂症患者与健康家庭成员,也不能区分有该疾病家族史的受试者与无家族史的受试者。